An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

Yoshinobu Maeda, Hisakazu Nishimori, Yoshihiro Inamoto, Hirohisa Nakamae, Masashi Sawa, Yasuo Mori, Kazuteru Ohashi, Shin ichiro Fujiwara, Mitsune Tanimoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

Original languageEnglish
Pages (from-to)409-412
Number of pages4
JournalActa Medica Okayama
Volume70
Issue number5
Publication statusPublished - 2016

Fingerprint

Graft vs Host Disease
Grafts
Refractory materials
Steroids
Acute Promyelocytic Leukemia
T-cells
Cell Transplantation
Tretinoin
Cell Differentiation
Cause of Death
Down-Regulation
Tissue Donors
Morbidity
T-Lymphocytes
tamibarotene
Therapeutics

Keywords

  • Am80
  • Chronic GVHD
  • Retinoid
  • Steroid-refractory GVHD
  • Tamibarotene

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease. / Maeda, Yoshinobu; Nishimori, Hisakazu; Inamoto, Yoshihiro; Nakamae, Hirohisa; Sawa, Masashi; Mori, Yasuo; Ohashi, Kazuteru; Fujiwara, Shin ichiro; Tanimoto, Mitsune.

In: Acta Medica Okayama, Vol. 70, No. 5, 2016, p. 409-412.

Research output: Contribution to journalArticle

Maeda, Y, Nishimori, H, Inamoto, Y, Nakamae, H, Sawa, M, Mori, Y, Ohashi, K, Fujiwara, SI & Tanimoto, M 2016, 'An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease', Acta Medica Okayama, vol. 70, no. 5, pp. 409-412.
Maeda, Yoshinobu ; Nishimori, Hisakazu ; Inamoto, Yoshihiro ; Nakamae, Hirohisa ; Sawa, Masashi ; Mori, Yasuo ; Ohashi, Kazuteru ; Fujiwara, Shin ichiro ; Tanimoto, Mitsune. / An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease. In: Acta Medica Okayama. 2016 ; Vol. 70, No. 5. pp. 409-412.
@article{9783372382624879bab5c071142868aa,
title = "An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease",
abstract = "Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.",
keywords = "Am80, Chronic GVHD, Retinoid, Steroid-refractory GVHD, Tamibarotene",
author = "Yoshinobu Maeda and Hisakazu Nishimori and Yoshihiro Inamoto and Hirohisa Nakamae and Masashi Sawa and Yasuo Mori and Kazuteru Ohashi and Fujiwara, {Shin ichiro} and Mitsune Tanimoto",
year = "2016",
language = "English",
volume = "70",
pages = "409--412",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

AU - Maeda, Yoshinobu

AU - Nishimori, Hisakazu

AU - Inamoto, Yoshihiro

AU - Nakamae, Hirohisa

AU - Sawa, Masashi

AU - Mori, Yasuo

AU - Ohashi, Kazuteru

AU - Fujiwara, Shin ichiro

AU - Tanimoto, Mitsune

PY - 2016

Y1 - 2016

N2 - Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

AB - Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

KW - Am80

KW - Chronic GVHD

KW - Retinoid

KW - Steroid-refractory GVHD

KW - Tamibarotene

UR - http://www.scopus.com/inward/record.url?scp=84997706142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997706142&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 409

EP - 412

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -